{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:58:36Z","timestamp":1762955916746,"version":"3.41.2"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T00:00:00Z","timestamp":1528156800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.00586","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T08:16:59Z","timestamp":1528186619000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic Potential of Enoxaparin in Lichen Planus: Exploring Reasons for Inconsistent Reports"],"prefix":"10.3389","volume":"9","author":[{"given":"Rahul P.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhur D.","family":"Shastri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long Chiau","family":"Ming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Tabish R.","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory M.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/j.1742-1241.2005.00589.x","article-title":"The management of lichen planus with low-molecular-weight heparin (enoxaparin).","volume":"59","author":"Akdeniz","year":"2005","journal-title":"Int. J. Clin. Pract."},{"key":"B2","first-page":"93","article-title":"Treatment of recalcitrant lichen planus with low molecular weight heparin (Enoxaparin): a case series study among Iraqi patients.","volume":"8","author":"Ameen","year":"2011","journal-title":"Med. J. Babylon"},{"key":"B3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40257-015-0160-6","article-title":"Treatments for cutaneous lichen planus: a systematic review and meta-analysis.","volume":"17","author":"Atzmony","year":"2016","journal-title":"Am. J. Clin. Dermatol."},{"key":"B4","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/j.1365-2036.2004.01926.x","article-title":"Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis.","volume":"19","author":"Bloom","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B5","article-title":"Treatment of ulcerative colitis with heparin.","volume":"110","author":"Brazier","year":"1996","journal-title":"Gastroenterology"},{"key":"B6","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1378\/chest.107.4.1009","article-title":"Effect of inhaled heparin on methacholine-induced bronchial hyperreactivity.","volume":"107","author":"Ceyhan","year":"1995","journal-title":"Chest"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006774.pub3","article-title":"Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.","volume":"6","author":"Chande","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"B8","first-page":"561","article-title":"\u201cLichen planus,\u201d in","author":"Daoud","year":"2012","journal-title":"Fitzpatrick\u2019s Dermatology in General Medicine"},{"key":"B9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/ibd.20085","article-title":"Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis.","volume":"13","author":"de Bievre","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/FTD.0000000000000233","article-title":"Compliance with enoxaparin dosing and monitoring guidelines and the impact on patient length of stay: a pilot study.","volume":"38","author":"Dekker","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"B11","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1023\/A:1011979418914","article-title":"Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial.","volume":"46","author":"Dotan","year":"2001","journal-title":"Dig. Dis. Sci."},{"key":"B12","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1046\/j.1365-2036.1997.00252.x","article-title":"Treatment of corticosteroid-resistant ulcerative colitis with heparin\u2013a report of 16 cases.","volume":"11","author":"Evans","year":"1997","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.clindermatol.2009.03.004","article-title":"Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies.","volume":"28","author":"Farhi","year":"2010","journal-title":"Clin. Dermatol."},{"key":"B14","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1046\/j.1468-3083.2003.00732.x","article-title":"Low-molecular-weight heparin (enoxaparin) in the treatment of lichen planus.","volume":"17","author":"Ferahbas","year":"2003","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/742826","article-title":"Cutaneous and mucosal lichen planus: a comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis.","volume":"2014","author":"Gorouhi","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"B16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.oooo.2012.03.013","article-title":"Salivary basic fibroblast growth factor in patients with oral squamous cell carcinoma or oral lichen planus.","volume":"114","author":"Gorugantula","year":"2012","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"B17","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S0190-9622(98)70118-5","article-title":"Low-dose low-molecular-weight heparin (enoxaparin) is beneficial in lichen planus: a preliminary report.","volume":"38","author":"Hodak","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"B18","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2340\/0001555574454456","article-title":"Low doses of low molecular weight heparin in vivo inhibits the elicitation of contact hypersensitivity.","volume":"74","author":"Ingber","year":"1994","journal-title":"Acta Derm. Venereol."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4103\/2277-9175.115798","article-title":"Comparison of therapeutic effect of low-dose low-molecular-weight heparin (enoxaparin) vs. oral prednisone in treatment of patients with lichen planus; A clinical trial.","volume":"2","author":"Iraji","year":"2013","journal-title":"Adv. Biomed. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.5125\/jkaoms.2015.41.4.171","article-title":"Proinflammatory cytokine levels in oral lichen planus, oral leukoplakia, and oral submucous fibrosis.","volume":"41","author":"Kaur","year":"2015","journal-title":"J. Korean Assoc. Oral Maxillofac. Surg."},{"key":"B21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3329\/jafmc.v9i1.18717","article-title":"Efficacy of low dose low molecular weight heparin in the treatment of cutaneous lichen planus.","volume":"9","author":"Khan","year":"2014","journal-title":"J. Armed Forces Med. Coll. Bangladesh"},{"key":"B22","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1586\/17512433.2015.1082425","article-title":"Heparins in ulcerative colitis: proposed mechanisms of action and potential reasons for inconsistent clinical outcomes.","volume":"8","author":"Lean","year":"2015","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1039\/c3ib40206a","article-title":"Identification of pro- and anti-proliferative oligosaccharides of heparins.","volume":"6","author":"Lean","year":"2014","journal-title":"Integr. Biol."},{"key":"B24","first-page":"87","article-title":"\u201cNon-Anticoagulant oligosaccharides of enoxaparin relieve chemical-induced acute colitis,\u201d in","author":"Lean","year":"2016","journal-title":"Advances in Medicine and Biology"},{"key":"B25","first-page":"441","author":"Lebwohl","year":"2017","journal-title":"Treatment of Skin Disease: Comprehensive Therapeutic Strategies"},{"key":"B26","first-page":"153","article-title":"A comparative study of methotrexate & low molecular weight heparin for the treatment of generalized lichen planus.","volume":"2","author":"Lunge","year":"2016","journal-title":"Indian J. Clin. Exp. Dermatol."},{"key":"B27","first-page":"37","article-title":"Treatment of severe cutaneous ulcerative lichen planus with low molecular weight heparin in a patient with hepatitis C.","volume":"79","author":"Neville","year":"2007","journal-title":"Cutis"},{"key":"B28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/095466301317085444","article-title":"Successful treatment of lichen planus with low-molecular-weight heparin: a case series of seven patients.","volume":"12","author":"Pacheco","year":"2001","journal-title":"J. Dermatolog. Treat."},{"key":"B29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jpba.2007.10.009","article-title":"A simple capillary electrophoresis method for the rapid separation and determination of intact low molecular weight and unfractionated heparins.","volume":"46","author":"Patel","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ab.2009.01.007","article-title":"Effective reversed-phase ion pair high-performance liquid chromatography method for the separation and characterization of intact low-molecular-weight heparins.","volume":"387","author":"Patel","year":"","journal-title":"Anal. Biochem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1002\/jps.21483","article-title":"Investigation of freezing- and thawing-induced biological, chemical, and physical changes to enoxaparin solution.","volume":"98","author":"Patel","year":"","journal-title":"J. Pharm. Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1002\/jps.21556","article-title":"Investigation of the effect of heating on the chemistry and antifactor Xa activity of enoxaparin.","volume":"98","author":"Patel","year":"","journal-title":"J. Pharm. Sci."},{"key":"B33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1183\/09031936.96.09020217","article-title":"The effect of inhaled heparin on bronchial reactivity to sodium metabisulphite and methacholine in patients with asthma.","volume":"9","author":"Pavord","year":"1996","journal-title":"Eur. Respir. J."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00126","article-title":"Molecular interactions between complement factor H and its heparin and heparan sulfate ligands.","volume":"5","author":"Perkins","year":"2014","journal-title":"Front. Immunol."},{"key":"B35","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/09629350410001688530","article-title":"Salivary levels of tumor necrosis factor-alpha in oral lichen planus.","volume":"13","author":"Pezelj-Ribaric","year":"2004","journal-title":"Mediators Inflamm."},{"key":"B36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1538-7836.2003.00014.x","article-title":"Low molecular weight heparins: are they interchangeable? Yes.","volume":"1","author":"Prandoni","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"B37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1067\/mjd.2002.117389","article-title":"Low-dose low-molecular-weight heparin in lichen planus.","volume":"46","author":"Rai","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"journal-title":"Product Information Clexane<sup>\u00ae<\/sup> and Clexane<sup>\u00ae<\/sup> Forte","year":"2017","key":"B38"},{"key":"B39","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1007\/s00216-013-6996-9","article-title":"Ion exchange chromatographic separation and isolation of oligosaccharides of intact low-molecular-weight heparin for the determination of their anticoagulant and anti-inflammatory properties.","volume":"405","author":"Shastri","year":"2013","journal-title":"Anal. Bioanal. Chem."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118798","article-title":"Opposing effects of low molecular weight heparins on the release of inflammatory cytokines from peripheral blood mononuclear cells of asthmatics.","volume":"10","author":"Shastri","year":"","journal-title":"PLoS One"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126763","article-title":"In-vitro suppression of IL-6 and IL-8 release from human pulmonary epithelial cells by non-anticoagulant fraction of enoxaparin.","volume":"10","author":"Shastri","year":"","journal-title":"PLoS One"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128803","article-title":"Non-anticoagulant fractions of enoxaparin suppress inflammatory cytokine release from peripheral blood mononuclear cells of allergic asthmatic individuals.","volume":"10","author":"Shastri","year":"","journal-title":"PLoS One"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1001\/archdermatol.2009.200","article-title":"Hepatitis C virus and lichen planus: a reciprocal association determined by a meta-analysis.","volume":"145","author":"Shengyuan","year":"2009","journal-title":"Arch. Dermatol."},{"key":"B44","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0003-9969(99)00013-8","article-title":"Distribution of interleukin-2, -4, -10, tumour necrosis factor-alpha and transforming growth factor-beta mRNAs in oral lichen planus.","volume":"44","author":"Simark-Mattsson","year":"1999","journal-title":"Arch. Oral Biol."},{"key":"B45","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1046\/j.1365-2133.1999.03202.x","article-title":"Low molecular weight heparin; a novel alternative therapeutic approach for lichen planus.","volume":"141","author":"Stefanidou","year":"1999","journal-title":"Br. J. Dermatol."},{"key":"B46","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1046\/j.1365-2036.1999.00599.x","article-title":"Low molecular weight heparin as adjuvant therapy in active ulcerative colitis.","volume":"13","author":"Torkvist","year":"1999","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B47","doi-asserted-by":"crossref","first-page":"172","DOI":"10.5799\/ahinjs.01.2012.02.0138","article-title":"The effectiveness of treatment with enoxaparin in lichen planus.","volume":"3","author":"U\u00e7mak","year":"2012","journal-title":"J. Clin. Exp. Invest."},{"key":"B48","first-page":"1","article-title":"\u201cHeparan sulfate proteoglycan in inflammation and angiogenesis,\u201d in","author":"Wang","year":"2011","journal-title":"Glycans in Diseases and Therapeutics"},{"key":"B49","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ijwd.2015.04.001","article-title":"Update on lichen planus and its clinical variants.","volume":"1","author":"Weston","year":"2015","journal-title":"Int. J. Womens Dermatol."},{"key":"B50","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4103\/0378-6323.74989","article-title":"The successful treatment of palmoplantar hyperkeratotic lichen planus with enoxaparin.","volume":"77","author":"Yasar","year":"2011","journal-title":"Indian J. Dermatol. Venereol. Leprol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.00586\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T00:04:40Z","timestamp":1693699480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.00586\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,5]]},"references-count":50,"alternative-id":["10.3389\/fphar.2018.00586"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.00586","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2018,6,5]]},"article-number":"586"}}